EP2041144A1 - Substituierte benzoxepino-isoxazole und ihre verwendung - Google Patents
Substituierte benzoxepino-isoxazole und ihre verwendungInfo
- Publication number
- EP2041144A1 EP2041144A1 EP07785863A EP07785863A EP2041144A1 EP 2041144 A1 EP2041144 A1 EP 2041144A1 EP 07785863 A EP07785863 A EP 07785863A EP 07785863 A EP07785863 A EP 07785863A EP 2041144 A1 EP2041144 A1 EP 2041144A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- formula
- substituted
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present application relates to novel, substituted benzoxepino-isoxazole derivatives, processes for their preparation, their use for the treatment and / or prophylaxis of diseases and their use for the preparation of medicaments for the treatment and / or prophylaxis of diseases, preferably for the treatment and / or Prevention of cardiovascular diseases, especially dyslipidaemias, arteriosclerosis, restenosis and ischemia.
- Isolated elevated plasma cholesterol is one of the biggest risk factors for cardiovascular diseases such as arteriosclerosis. This concerns both isolated hypercholesterolemia and hypercholesterolemias combined with e.g. elevated plasma triglycerides or low plasma HDL cholesterol. Substances which are cholesterol- or combined-cholesterol- and triglyceride-lowering agents should therefore be suitable for the treatment and prevention of cardiovascular diseases.
- squalene synthase inhibitors reduce plasma cholesterol and triglycerides in the animal model.
- Squalene synthase (EC 2.5.1.21) catalyzes the conversion of farnesyl pyrophosphate to squalene by reductive condensation. This is a crucial step in cholesterol biosynthesis. While farnesyl pyrophosphate and precursors are also important for other cellular metabolic pathways and responses, squalene serves exclusively as a precursor to cholesterol. An inhibition of squalene synthase thus leads directly to the reduction of cholesterol biosynthesis and thus to a reduction in plasma cholesterol levels. In addition, it has been shown that squalene synthase inhibitors also reduce plasma triglyceride levels.
- Inhibitors of squalene synthase could thus be used for the treatment and / or prevention of cardiovascular diseases, such as, for example, dyslipidaemias, arteriosclerosis, ischemia / reperfusion, restenosis and arterial inflammation [cf. e.g. Eur. Heart J.j9 (Suppl. A), A2-A11 (1998); Prog. Med. Chem. 33, 331-378 (1996); Europ. J. Pharm. 43JL, 345-352 (2001)].
- cardiovascular diseases such as, for example, dyslipidaemias, arteriosclerosis, ischemia / reperfusion, restenosis and arterial inflammation [cf. e.g. Eur. Heart J.j9 (Suppl. A), A2-A11 (1998); Prog. Med. Chem. 33, 331-378 (1996); Europ. J. Pharm. 43JL, 345-352 (2001)].
- WO 2005/068472 discloses certain tricyclic benzazepine derivatives as squalene synthase inhibitors.
- the present invention relates to compounds of the general formula (I)
- (C 6 -C 10) -aryl or 5- to 10-membered heteroaryl which are in each case up to three times, identically or differently, selected from substituents selected from the group halogen, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C, -C 6 ) alkyl, (C 2 -C 6) alkenyl, (C 2 -C 6) - alkynyl, (C r C 6) alkoxy, hydroxy, amino, mono- and di- (C r C6) alkylamino can be substituted
- n is the number 0, 1, 2 or 3
- R 1 and R 2 are the same or different and are independently hydrogen, halogen, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C r C6) alkyl or (Ci-C 6) alkoxy,
- R 3 is (C, -C 8) alkyl, (C 2 -C 8) alkenyl, (C 2 -C 8) -alkynyl, which may be sub- stituiert with (C 3 -C 8) -cycloalkyl, or is (C 3 -C 8 ) -cycloalkyl, wherein
- R 4 is a group of the formula -OR 5 or -NR 6 R 7 , wherein
- R 5 is hydrogen or (C 1 -C 6 ) -alkyl
- R 6 and R 7 are the same or different and are independently hydrogen, (Ci-C 6) - alkyl or (C 3 -C 8) cycloalkyl, the substituents selected from the group carboxyl, (C, -C 6) - Alkoxycarbonyl, aminocarbonyl, mono- and di- (C r C 6 ) alkyl aminocarbonyl may be substituted mean
- R 8 denotes hydrogen, (C r C4) alkyl, (C r C4) -acyl or (C r C 4) alkoxycarbonyl,
- Compounds according to the invention are the compounds of the formula (I) and their salts, solvates and solvates of the salts comprising the compounds of the formulas below and their salts, solvates and solvates of the salts and of the formula (I) encompassed by formula (I), hereinafter referred to as exemplary compounds and their salts, solvates and solvates of the salts, as far as the compounds of formula (I), the compounds mentioned below are not already salts, solvates and solvates of the salts.
- the compounds of the invention may exist in stereoisomeric forms (enantiomers, diastereomers).
- the invention therefore includes the enantiomers or diastereomers and their respective mixtures. From such mixtures of enantiomers and / or diastereomers, the stereoisomerically uniform components can be isolated in a known manner.
- the present invention encompasses all tautomeric forms.
- physiologically acceptable salts of the compounds according to the invention are preferred in the context of the present invention. Also included are salts which are themselves unsuitable for pharmaceutical applications but can be used, for example, for the isolation or purification of the compounds of the invention.
- Physiologically acceptable salts of the compounds of the invention include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, e.g. Salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.
- salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid acetic acid, trifluoroacetic acid, propionic acid
- Physiologically acceptable salts of the compounds according to the invention also include salts of customary bases, such as, by way of example and by way of preference, alkali metal salts (for example sodium and potassium salts), alkaline earth salts (for example calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms, such as, by way of example and by way of illustration, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylenediamine and N-methylpiperidine.
- customary bases such as, by way of example and by way of preference, alkali metal salts (for example sodium and potassium salts), alkaline earth salts (for example calcium and magnesium salts
- solvates are those forms of the compounds according to the invention which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates that coordinate with water. As solvates, hydrates are preferred in the context of the present invention.
- the present invention also includes prodrugs of the compounds of the invention.
- prodrugs includes compounds which may themselves be biologically active or inactive, but are reacted during their residence time in the body to compounds according to the invention (for example metabolically or hydrolytically).
- (C r Cs) alkyl, (C 1 -Q) -alkyl and (C 1 -C) -alkyl are in the context of the invention a straight-chain or branched alkyl radical having 1 to 8, 1 to 6 or 1 to 4 carbon atoms. Preference is given to a straight-chain or branched alkyl radical having 1 to 6 or 1 to 4 carbon atoms.
- a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. atoms. Examples which may be mentioned are: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, 1-ethylpropyl, n-pentyl and n-hexyl.
- fC 2 -Cg -alkenyl and (C 2 -C 15) -alkenyl are a straight-chain or branched alkenyl radical having 2 to 8 or 2 to 6 carbon atoms and one or two double bonds. Preference is given to a straight-chain or branched alkenyl radical having 2 to 6, particularly preferably 2 to 4, carbon atoms and one double bond.
- (C 2 -Cs) -AlkJnVl and (C 2 -Cn) -AlkJnVl represent a straight-chain or branched alkynyl radical having 2 to 8 or 2 to 6 carbon atoms and a triple bond. Preference is given to a straight-chain or branched alkynyl radical having 2 to 6, particularly preferably 2 to 4, carbon atoms.
- (C r C ") - Cvcloalkyl and (C r Cfi) -Ccloalkyl are in the context of the invention for a monocyclic, saturated cycloalkyl group having 3 to 8 or 3 to 6 carbon atoms. Preference is given to a cycloalkyl radical having 3 to 6 carbon atoms. Examples which may be mentioned by way of example include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
- aryl is in the context of the invention an aromatic radical having preferably 6 to 10 carbon atoms.
- Preferred aryl radicals are phenyl and naphthyl.
- in the context of the invention are a straight-chain or branched alkoxy radical having 1 to 6 or 1 to 4 carbon atoms. Preference is given to a straight-chain or branched alkoxy radical having 1 to 4 carbon atoms. Examples which may be mentioned are: methoxy, ethoxy, n-propoxy, isopropoxy and tert-butoxy.
- (C 1 -C 4) -alkoxycarbonyl and (C 1 -C 4) -alkoxycarbonyl are in the context of the invention a straight-chain or branched alkoxy radical having 1 to 6 or 1 to 4 carbon atoms which is linked via a carbonyl group. Preference is given to a straight-chain or branched alkoxycarbonyl radical having 1 to 4 carbon atoms in the alkoxy group. Examples which may be mentioned by way of example include: methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl and tert. Butoxycarbonyl.
- Mono (C 1 -C) -alkylamino and mono (C 1 -C 4) -alkylamino in the context of the invention are an amino group having a straight-chain or branched alkyl substituent which is 1 to 6 or
- Having 1 to 4 carbon atoms Preference is given to a straight-chain or branched monoalkyl amino radical having 1 to 4 carbon atoms. Examples which may be mentioned by way of example include methylamino, ethylamino, n-propylamino, isopropylamino and tert-butylamino.
- Di- (C 1 -Cfi ' ) -Alkylamino and di- (C r C j ) alkylamino stand in the context of the invention for an amino group having two identical or different straight-chain or branched alkyl substituents, each of 1 to 6 or Have 1 to 4 carbon atoms.
- Straight-chain or branched dialkylamino radicals having in each case 1 to 4 carbon atoms are preferred.
- N N-dimethylamino, N, N-diethylamino, N-ethyl-N-methylamino, N-methyl-Nn-propylamino, N-isopropyl-Nn-propylamino, N-tert-butyl N-methylamino, N-ethyl-Nn-pentylamino and Nn-hexyl-N-methylamino.
- Mono- or di-fCpC ⁇ Valkylaminocarbonyl or mono- or di-fCyCjValkylaminocarbonyl stand in the context of the invention for an amino group which is linked via a carbonyl group and a straight-chain or branched or two identical or different straight-chain or branched alkyl substituents each having 1 to 6 or 1 to 4 carbon atoms.
- Examples which may be mentioned by way of example and with preference are: methylaminocarbonyl, ethylaminocarbonyl, isopropylaminocarbonyl, tert-butylaminocarbonyl, N, N-dimethylaminocarbonyl, N, N-diethylaminocarbonyl, N-ethyl-N-methylaminocarbonyl and N-tert-butyl-N- methylaminocarbonyl.
- (C r Cd) acyl [(C r C 4 ) alkanoyl] in the context of the invention is a straight-chain or branched alkyl radical having 1 to 4 carbon atoms which carries a doubly bonded oxygen atom in the 1-position and Position is linked. Examples which may be mentioned are: formyl, acetyl, propionyl, n-butyryl and isobutyryl.
- CiVAcyloxy is in the context of the Erfindung- a straight-chain or branched alkyl radical having 1 to 4 carbon atoms which carries in the 1-position a doubly bonded oxygen atom and is linked in the 1-position via a further oxygen atom.
- Exemplary and Preferred are: acetoxy, propionoxy, n-butyroxy and iso-butyroxy.
- 5- to 10-membered heteroaryl in the context of the invention is a mono- or optionally bicyclic aromatic heterocycle (heteroaromatic) having up to three identical or different heteroatoms from the series ⁇ , O and / or S, via a ring carbon atom or optionally a ring nitrogen atom of the heteroaromatic is linked.
- heteroaryl in the context of the invention is a mono- or optionally bicyclic aromatic heterocycle (heteroaromatic) having up to three identical or different heteroatoms from the series ⁇ , O and / or S, via a ring carbon atom or optionally a ring nitrogen atom of the heteroaromatic is linked.
- 5- to 6-membered heteroaryl radicals having up to two Heteroatoms from the series N, O and / or S such as furyl, thienyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, imidazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl.
- a 4- to 8-, 5- to 7- or 5- to 6-membered heterocycle is in the context of the invention for a saturated or partially unsaturated heterocycle having a total of 4 to 8, 5 to 7 or 5 to 6 ring atoms, the contains a ring nitrogen atom linked via this and another
- Heteroatom from the series N, O, S, SO or SO 2 may contain.
- Preferred is a 5- to 7-membered saturated, N-linked heterocycle which may contain another heteroatom from the series N, O or S.
- Examples which may be mentioned are: pyrrolidinyl, pyrrolinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, azepinyl, 1,4-diazepinyl.
- Particularly preferred are piperidinyl, piperazinyl, morpholinyl and pyrrolidinyl.
- Halogen in the context of the invention includes fluorine, chlorine, bromine and iodine. Preference is given to chlorine or fluorine.
- radicals are substituted in the compounds according to the invention, the radicals can, unless otherwise specified, be monosubstituted or polysubstituted. In the context of the present invention, it applies that for all radicals which occur repeatedly, their meaning is independent of one another. Substitution with one, two or three identical or different substituents is preferred. Very particular preference is given to the substitution with a substituent.
- A is phenyl, naphthyl or pyridyl, which are each up to twice, identical or different, by substituents selected from the group of fluorine, chlorine, bromine, cyano, nitro,
- Trifluoromethyl, trifluoromethoxy, (C r C4) alkyl, (C r C4) alkoxy, hydroxy, amino, mono- and di- (Ci-C4) - alkylamino may be substituted
- n is the number 0 or 1
- R 1 and R 2 are the same or different and are independently hydrogen, fluorine, chlorine, bromine, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C r C4) alkyl or (C r C 4) alkoxy,
- R 3 is (C r C6) alkyl which may be substituted with (C 3 -C 6) cycloalkyl, or (C 3 -C 6) - is cycloalkyl wherein
- (Ci-C 6) -alkyl and (C 3 -C 6) cycloalkyl can be substituted by hydroxy, amino, (Ci-C 4) -alkoxy or (C r C 4) acyloxy, and
- R 4 is a group of the formula -OR 5 or -NR 6 R 7 , wherein
- R 5 is hydrogen or (C 1 -C 6 ) -alkyl
- R 6 and R 7 are the same or different and are independently hydrogen, (Ci-C 6) - alkyl or (C 3 -C 6) -cycloalkyl, by Substiruenten selected from the group
- Carboxyl, (Ci-C 6 ) alkoxycarbonyl, aminocarbonyl, mono- and di- (C r C 6 ) alkyl aminocarbonyl may be substituted mean
- R 6 and R 7 together with the nitrogen atom to which they are bonded, contain a 5- to 7-membered heterocycle containing a further ring heteroatom from the series NR 8 , O or S and by substituents selected from the group consisting of hydroxyl,
- Mono- and di- (C r C 6 ) alkylaminocarbonyl may be substituted, in which
- (C r C6) -alkyl for its part, by substituents selected from the group of hydroxy, amino, carboxyl, (C r C 6) alkoxycarbonyl, aminocarbonyl, mono- and di- (Cp
- R 8 is hydrogen, (C 1 -C 4 ) -alkyl, (C 1 -C 4 ) -acyl or (C 1 -C 4 ) -alkoxycarbonyl,
- A is phenyl which is monosubstituted or disubstituted, identically or differently, by fluorine, chlorine, bromine, methyl, methoxy, ethoxy or dimethylamino,
- n stands for the number 0
- R 1 and R 2 are independently hydrogen or chlorine
- R 3 is (C
- R 4 is a group of the formula -OR 5 or -NR 6 R 7 , wherein
- R 5 is hydrogen or (C 1 -C 4 ) -alkyl
- R 6 and R 7 are the same or different and are independently hydrogen or (C r C 4) alkyl which may be substituted with carboxyl or (Ci-C 4) alkoxycarbonyl, mean
- R 8 denotes hydrogen, (C r C4) alkyl or (C r C 4) acyl
- A is phenyl which is monosubstituted or disubstituted, identical or different, by fluorine, chlorine, methyl, methoxy or ethoxy,
- n stands for the number 0
- R 'and R 2 are independently hydrogen or chlorine
- R 3 is (C 1 -C 6 ) -alkyl
- R 4 is hydroxy or a group of the formula -NR 6 R 7 , wherein
- R 6 and R 7 together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocycle containing a further ring heteroatom from the series NR 8 and O and with hydroxy, oxo, (dC 4 ) Alkyl, carboxyl or (CI)
- (Ci-C 4) -alkyl for its part may be substituted with hydroxy, carboxyl or (C r C 4) alkoxycarbonyl
- R 8 is hydrogen, methyl or acetyl
- the invention further provides a process for the preparation of the compounds according to the invention, which comprises reacting a compound of the formula (II)
- R 9 is hydrogen, (C r C 6 ) -alkyl or (C 3 -C 6 ) -cycloalkyl or both radicals R 9 together form a ortho-phenylene-, -CH 2 -CH 2 -, -C (CH 3 ) 2 -C (CH 3 ) 2 -, -CH 2 -C (CHj) 2 -CH 2 - or -CH 2 -CHR 10 -CH 2 - form bridge, wherein
- R 10 is hydrogen, (C 1 -C 4 ) -alkyl or (C 1 -C 4 ) -alkoxy, in an inert solvent under basic conditions with a compound of formula (III)
- R " is (C r C 6 ) -alkyl or (C 3 -C 6 ) -cycloalkyl or both radicals R 1 1 together form an or / a-phenylene-, -CH 2 -CH 2 -, -C (CH 3 ) 2 -C (CH 3 ) 2 -, -CH 2 -C (CHj) 2 -CH 2 - or -CH 2 -CHR 12 - to form CH 2 - bridge, wherein
- R 12 is hydrogen, (C r C4) alkyl or (C, -C 4) alkoxy,
- R, R and A each have the meanings given above
- X represents halogen, in particular chlorine, bromine or iodine, or a halogen equivalent by way of example and preferably from the group of the alkyl sulfonates or aryl sulfonates, such as, for example, mesylate, triflate, tresylate, nonaflate or tosylate,
- T is (C r C4) alkyl
- R 1 , R 2 , R 3 , A and n each have the meanings given above, but n does not stand for the number 0,
- R 5 , R 6 and R 7 each have the meanings given above, but R 5 does not stand for hydrogen
- a separation of the compounds according to the invention into the corresponding enantiomers and / or diastereomers may be carried out, as appropriate, at the stage of the compounds (I-A), (I-B), (I-C) or (I); such a separation of the stereoisomers can be carried out by methods known to the person skilled in the art, preferably by chromatographic means.
- Inert solvents for process step (II) + (III) ⁇ (IV) are, for example, ethers, such as diethyl ether, tert-butyl methyl ether, dioxane, tetrahydrofuran, glycol dimethyleher or diethylene glycol dimethyl ether, hydrocarbons, such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, halogenated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, 1, 2-dichloroethane, trichlorethylene or chlorobenzene, or other solvents such as ethyl acetate, dimethylformamide or acetonitrile. It is likewise possible to use mixtures of the solvents mentioned. Preference is given to diethyl ether and glycol dimethyl ether (1,2-dimethoxyethane).
- Suitable bases are the customary inorganic or organic bases. These include in particular alkali metal bicarbonates such as sodium or potassium bicarbonate or amines such as triethylamine. Preference is given to potassium hydrogencarbonate.
- the compound of formula (III) is in this case used in an amount of 0.5 to 5 mol, preferably from 1 to 1.5 mol, based on 1 mol of the compound of formula (II).
- the reaction is generally carried out in a temperature range of +20 0 C to +150 0 C, preferably at +50 0 C to + 8O 0 C.
- the reaction can be carried out at normal, elevated or at reduced pressure (eg from 0.5 to 5 bar). Generally, one works at normal pressure.
- the reaction (IV) + (V) ⁇ (VI) ["Suzuki reaction”; see. eg Suzuki et al., Synlett 3, 207-210 (1992); Suzuki et al., Chem. Rev. 95, 2457-2483 (1995)] is carried out in the presence of a transition metal catalyst, such as palladium or nickel catalysts, and a base.
- a transition metal catalyst such as palladium or nickel catalysts
- Suitable solvents for this reaction are inert organic solvents which do not change under the reaction conditions. These include, for example, ethers such as diethyl ether, tert-butyl methyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, or other solvents such as ethyl acetate, dimethylformamide or acetonitrile. It is likewise possible to use mixtures of the solvents mentioned. Dioxane is preferably used.
- Suitable bases for reaction (IV) + (V) -> (VI) are customary inorganic or organic bases. These include in particular alkali metal carbonates such as sodium, potassium or cesium carbonate, alkali metal hydroxides such as lithium, sodium or potassium hydroxide, alkaline earth metal hydroxides such as barium hydroxide, alkali metal fluorides such as sodium, potassium or cesium fluoride, alkali metal such as sodium, alkaline phosphates such as potassium phosphate, or organic amines such as triethylamine. Preference is given to potassium phosphate.
- alkali metal carbonates such as sodium, potassium or cesium carbonate
- alkali metal hydroxides such as lithium, sodium or potassium hydroxide
- alkaline earth metal hydroxides such as barium hydroxide
- alkali metal fluorides such as sodium, potassium or cesium fluoride
- alkali metal such as sodium, alkaline phosphates such as potassium phosphate, or organic amines such as trie
- Suitable transition metal catalysts are, for example, [l, l 'bis (diphenylphosphino) ferrocenes] dichloropalladium (II), bis (triphenylphosphine) palladium (II) chloride or tetrakis (triphenylphosphine) palladium (O), or mixtures of transition metal complexes with complexing ligands such as bis (dibenzylideneacetone) palladium (0) / bis (diphenylphosphino) ferrocene or bis (dibenzylideneacetone) palladium (0) / tri-terf.- butylphosphine, or mixtures of transition metal salts with complex ligands such as palladium (II) acetate / tri-ortho / tolyl- phosphine.
- complexing ligands such as bis (dibenzylideneacetone) palladium (0) / bis (diphen
- the catalyst is used here in an amount of 0.001 to 1 mol, preferably from 0.01 to 0.2 mol, based on 1 mol of the compound of formula (IV).
- the compound of the formula (IV) is used in an amount of from 0.5 to 5 mol, preferably from 1 to 2.5 mol, based on 1 mol of the compound of the formula (V).
- the reaction is generally carried out in a temperature range of +20 0 C to +150 0 C, preferably at + 60 ° C to +100 0 C.
- the reaction can be carried out at normal, elevated or at reduced pressure (eg from 0.5 to 5 bar). Generally, one works at normal pressure.
- Inert solvents for process step (VI) -> (VII) are, for example, ethers, such as diethyl ether, tert-butyl methyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, alcohols, such as methanol, ethanol, n-propanol, where-propanol, n-butanol or ter /.
- Butanol, or dipolar aprotic solvents such as acetone, dimethylformamide, dimethyl sulfoxide or acetonitrile, or water. It is likewise possible to use mixtures of the solvents mentioned. Preference is given to tetrahydrofuran / water mixtures.
- Suitable acids for process step (VI) ⁇ (VII) are aqueous solutions of the customary inorganic acids, such as, for example, hydrochloric acid, sulfuric acid, phosphoric acid or hydrobromic acid.
- organic acids such as formic acid, trifluoroacetic acid, trifluoromethanesulfonic acid or p-toluenesulfonic acid can be used, each with the addition of water.
- acidic ion exchange resins such as Amberlyst ® 15, Dowex 50WX8 ®, Amberlite IR-120 ® or CT269 Purolite ® suitable. Hydrochloric acid is preferably used.
- the reaction is generally carried out in a temperature range of +20 0 C to + 15O 0 C, preferably at +50 0 C to + 100 ° C.
- the reaction can be carried out at normal, elevated or reduced pressure (for example from 0.5 to 5 bar). Generally, one works at normal pressure.
- Inert solvents for process step (VII) -> (VIII) are, for example, ethers, such as diethyl ether, tert-butyl methyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons, such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, halogenated hydrocarbons such as dichloromethane, trichloromethane or chlorobenzene, or other solvents such as ethyl acetate or acetonitrile. It is likewise possible to use mixtures of the solvents mentioned. Preference is given to using tetrahydrofuran, dichloromethane or toluene.
- Suitable phosphorus ylides or phosphoryls for the Wittig reaction are, for example, ethoxycarbonylmethylene-triphenylphosphorane or tert. Butoxycarbonylmethylene-triphenylphosphorane. These phosphorus ylides or ylenzenes are also from the corresponding phosphonium salts, such as ethoxycarbonylmethyltriphenylphosphonium bromide, by the action of a base, such as, for example, sodium hydride, potassium tert-butoxide or 1,5,7-triazabicyclo [4.4.0] - dec-5-en, accessible.
- a base such as, for example, sodium hydride, potassium tert-butoxide or 1,5,7-triazabicyclo [4.4.0] - dec-5-en, accessible.
- the above-described ylides or Ylene are in this case used in an amount of 0.5 to 5 mol, preferably from 1 to 1.5 mol, based on 1 mol of the compound of formula (VII).
- the reaction is generally carried out in a temperature range from -4O 0 C to + 100 0 C, preferably at O 0 C to + 40 0 C.
- the reaction can be carried out at normal, elevated or at reduced pressure (eg from 0.5 to 5 bar). Generally, one works at normal pressure.
- Inert solvents for process step (VIII) ⁇ (IX) are, for example, ethers, such as diethyl ether, tert-butyl methyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, alcohols, such as methanol, ethanol, n-propanol, and -propanol , n-butanol or tert-butanol, or hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, or other solvents such as ethyl acetate. It is likewise possible to use mixtures of the solvents mentioned. Preference is given to using tetrahydrofuran.
- Suitable reducing agents are boron or aluminum hydrides such as, for example, lithium borohydride, sodium borohydride, potassium borohydride or lithium tri- (tert.-butyloxy) -aluminum hydride. Preference is given to using lithium tri (tert-butyloxy) aluminum hydride.
- the reaction is generally carried out in a temperature range from -40 0 C to + 100 0 C, preferably at 0 0 C to + 40 0 C.
- the reaction can be carried out at normal, elevated or at reduced pressure (eg from 0.5 to 5 bar ). Generally, one works at normal pressure.
- Inert solvents for process step (IX) ⁇ (IA) are, for example, ethers, such as diethyl ether, tert-butyl methyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons, such as benzene, toluene, xylene, hexane, cyclohexane or natural oleic fractions, halogenated hydrocarbons such as dichloromethane or chlorobenzene, or other solvents such as ethyl acetate or Dimefhylformamid. It is likewise possible to use mixtures of the solvents mentioned. Preference is given to tetrahydrofuran.
- Suitable bases are the customary inorganic or organic bases. These include in particular alkali metal carbonates such as sodium, potassium or cesium carbonate, or phosphazene bases, such as l-ter ⁇ -butyl-2,2,4,4,4-pentakis (dimethylamino) -2 5, 4 5 -catenadiphospha- zen (phosphazene base P 2 -tert.-Bu). Preference is given to cesium carbonate or the phosphazene base? 2- tert.-Bu used.
- the reaction is generally carried out in a temperature range from -40 0 C to + 100 0 C, preferably at 0 0 C to + 40 0 C.
- the reaction can be carried out at normal, elevated or at reduced pressure (eg from 0.5 to 5 bar ). Generally, one works at normal pressure.
- Inert solvents for process step (IA) ⁇ (IB) are, for example, ethers, such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, alcohols, such as methanol, ethanol, -P -propanol,--propanol or j-butanol, or dipolar aprotic solvents such as acetone, dimethylformamide, dimethyl sulfoxide or acetonitrile, or else water. It is likewise possible to use mixtures of the solvents mentioned. Dioxane / water mixtures are preferably used.
- Suitable acids are aqueous solutions of the customary inorganic acids such as, for example, hydrochloric acid, sulfuric acid, phosphoric acid or hydrobromic acid. Preference is given to hydrochloric acid.
- the reaction is generally carried out in a temperature range of +20 0 C to + 150 ° C, preferably at + 5O 0 C to +100 0 C.
- the reaction can be carried out at normal, elevated or at reduced pressure (eg from 0.5 to 5 bar). Generally, one works at normal pressure.
- the process step (I-B) -> (I) or (I-C) -> (I) is carried out by literature methods for the esterification or amidation (amide formation) of carboxylic acids.
- Inert solvents for an amidation in process step (IB) + (XI) ⁇ (I) or (IC) + (XI) -> (I) are, for example, ethers, such as diethyl ether, tert-butyl methyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, halogenated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, 1,2-dichloroethane, trichlorethylene or chlorobenzene, or other solvents such as acetone, ethyl acetate, pyridine, dimethylsulfoxide, dimethylformamide, N , N'-dimethylpropyleneurea (DMPU), N-methylpyrroli
- Suitable condensing agents for amide formation in process step (IB) + (XI) -> (I) or (IC) + (XI) - »(I) are, for example, carbodiimides such as N, N'-diethyl, NN'-dipropyl , N, N'-diisopropyl, N, N'-dicyclohexylcarbodiimide (DCC) or N- (3-dimethylaminoisopropyl) -N'-ethylcarbodiimide hydrochloride (EDC), phosgene derivatives such as N, N - Carbonyldiimidazole (CDI), 1, 2-oxazolium compounds such as 2-ethyl-5-phenyl-l, 2-oxazolium-3-sulfate or 2-ter ⁇ -butyl-5-methylisoxazolium perchlorate, acylamino compounds such as 2-ethoxy -l-ethoxycarbonyl
- Amide formation in process step (IB) + (XI) ⁇ (I) or (IC) + (XI) ⁇ (I) is generally carried out in a temperature range from 0 ° C to +100 0 C, preferably from 0 0 C to + 40 ° C performed.
- the reaction can be carried out at normal, elevated or at reduced pressure (for example from 0.5 to 5 bar). Generally, one works at normal pressure.
- the compounds of the formula (V) can be prepared analogously to processes known from the literature by reacting a compound of the formula (XII)
- M is lithium or the Grignard radical -MgCl, -MgBr or -MgI,
- the compounds according to the invention have valuable pharmacological properties and can be used for the prevention and treatment of diseases in humans and animals.
- the compounds according to the invention are highly effective inhibitors of squalene synthase and inhibit cholesterol biosynthesis.
- the compounds according to the invention bring about a lowering of the cholesterol level and of the triglyceride level in the blood. They can therefore be used for the treatment and prevention of cardiovascular diseases, in particular hypolipoproteinemia, dyslipidaemias, hyperlipidemias, arteriosclerosis, restenosis and ischaemias.
- cardiovascular diseases in particular hypolipoproteinemia, dyslipidaemias, hyperlipidemias, arteriosclerosis, restenosis and ischaemias.
- the compounds according to the invention can also be used for the treatment and prevention of obesity and obesity.
- the compounds according to the invention are furthermore suitable for the treatment and prevention of strokes (stroke) and Alzheimer's disease.
- Another object of the present invention is the use of the compounds of the invention for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases.
- Another object of the present invention is the use of the compounds of the invention for the manufacture of a medicament for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases.
- Another object of the present invention is a method for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases, using an effective amount of at least one of the compounds of the invention.
- compositions containing at least one compound of the invention and at least one or more other active ingredients are pharmaceutical compositions containing at least one compound of the invention and at least one or more other active ingredients, in particular for the treatment and / or prophylaxis of the aforementioned diseases.
- suitable combination active ingredients are cholesterol-lowering statins, cholesterol absorption inhibitors, HDL-increasing or triglyceride-lowering and / or apolipoprotein B-lowering substances, antioxidants or antiinflammatory compounds.
- Combinations with these active substances are preferably suitable for the treatment of dyslipidaemias, combined hyperlipidaemias, hypercholesterolemias or hypertioglyceridemias.
- the combinations mentioned can also be used for the primary or secondary prevention of coronary heart diseases (eg myocardial infarction) as well as in peripheral arterial diseases.
- Statins in the context of the invention are, for example, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin and pitavastatin.
- Cholesterol absorption inhibitors are, for example, cholestyramine or ezetimibe; HDL-increasing or triglyceride-lowering or apolipoprotein B-lowering substances are, for example, fibrates, niacin, PPAR agonists as well as IBAT, MTP and CETP inhibitors.
- Anti-inflammatory compounds are, for example, aspirin.
- Another object of the present invention is also the combination of the compounds of the invention with a glucosidase and / or amylase inhibitor for the treatment of familial hyperlipidemia, obesity (obesity) and diabetes mellitus.
- Glucosidase and / or amylase inhibitors in the context of the invention are, for example, acarbose, adiposine, voglibose, miglitol, emiglitate, MDL-25637, camiglibose (MDL-73945), tendamita, AI-3688, trestatin, pradimicin-Q and salbostatin. Preference is given to the combination of acarbose, miglitol, emiglitate or voglibose with one of the compounds according to the invention.
- the compounds according to the invention can act systemically and / or locally.
- they may be applied in a suitable manner, e.g. oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctivae otic or as an implant or stent.
- the compounds according to the invention can be administered in suitable administration forms.
- the inventive compounds rapidly and / or modified donating application forms containing the compounds of the invention in crystalline and / or amorphized and / or dissolved form, such.
- Tablets uncoated or coated tablets, for example with enteric or delayed-release or insoluble coatings which control the release of the compound of the invention
- parenteral administration can be done bypassing a resorption step (eg, intravenous, intraarterial, intracardiac, intraspinal, or intralumbar) or with involvement of resorption (eg, intramuscular, subcutaneous, intracutaneous, percutaneous, or intraperitoneal).
- a resorption step eg, intravenous, intraarterial, intracardiac, intraspinal, or intralumbar
- suitable application forms include injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
- inhalation medicines including powder inhalers, nebulizers
- nasal drops solutions or sprays
- lingual, sublingual or buccal tablets to be applied films / wafers or capsules
- suppositories ear or Brighton Masonpa- rations
- vaginal capsules aqueous Suspensions (lotions, shake mixtures)
- lipophilic Sus pensions ointments
- creams transdermal therapeutic systems (eg patches)
- transdermal therapeutic systems eg patches
- milk pastes, foams, powder, implants or stents.
- the compounds according to the invention can be converted into the stated administration forms. This can be done in a conventional manner by mixing with inert, non-toxic, pharmaceutically suitable excipients.
- excipients for example microcrystalline cellulose, lactose, mannitol
- solvents for example liquid polyethylene glycols
- emulsifiers and dispersants or wetting agents for example sodium dodecyl sulfate, polyoxysorbitanoleate
- binders for example polyvinylpyrrolidone
- synthetic and natural polymers for example albumin
- Stabilizers eg, antioxidants such as ascorbic acid
- dyes eg, inorganic pigments such as iron oxides
- flavor and / or odoriferous include, among others.
- Excipients for example microcrystalline cellulose, lactose, mannitol
- solvents for example liquid polyethylene glycols
- emulsifiers and dispersants or wetting agents for example sodium dodecy
- compositions containing at least one compound of the invention usually together with one or more inert, non-toxic, pharmaceutically suitable excipients, and their use for the purposes mentioned above.
- parenteral administration amounts of about 0.001 to 1 mg / kg, preferably about 0.01 to 0.5 mg / kg body weight to achieve effective results.
- the dosage is about 0.01 to 100 mg / kg, preferably about 0.01 to 20 mg / kg and most preferably 0.1 to 10 mg / kg of body weight.
- Instrument Micromass GCT, GC 6890; Column: Restek RTX-35MS, 30 m ⁇ 250 ⁇ m ⁇ 0.25 ⁇ m; constant flow with helium: 0.88 ml / min .; Oven: 60 ° C; Inlet: 25O 0 C; Gradient: 60 0 C (hold for 0.30 min), 50 ° C / min. ⁇ 120 0 C, 16 ° C / min. ⁇ 250 0 C, 30 ° C / min. ⁇ 300 ° C (hold for 1.7 minutes).
- Device type MS Micromass ZQ
- Device type HPLC Waters Alliance 2795
- Column Phenomenex Synergi 2 ⁇ Hydro-RP Mercury, 20 mm x 4 mm
- Eluent A 1 liter of water + 0.5 ml of 50% formic acid
- Eluent B 1 liter acetonitrile + 0.5 ml 50% formic acid; Gradient: 0.0 min. 90% A ⁇ 2.5 min. 30% A ⁇ 3.0 min. 5% A ⁇ 4.5 min. 5% A; River: 0.0 min. 1 ml / min. ⁇ 2.5 min./3.0 min./4.5 min. 2 ml / min .; Oven: 50 ° C .; UV detection: 210 nm.
- Device type MS Micromass ZQ
- Device type HPLC HP 1100 Series
- UV DAD Column: Phenomenex Synergi 2 ⁇ Hydro-RP Mercury, 20mm x 4mm
- Eluent A 1 l of water + 0.5 ml of 50% formic acid
- eluent B 1 l of acetonitrile + 0.5 ml of 50% formic acid
- Oven 50 ° C .
- UV detection 210 nm.
- the reaction mixture is stirred for 2 h at -78 ° C and then added dropwise to work up with 70 ml of a 1 N solution of hydrogen chloride in diethyl ether.
- the mixture is warmed to room temperature and concentrated on a rotary evaporator.
- the residue is stirred with 50 ml of diethyl ether, the precipitate is filtered off and washed twice with 10 ml of diethyl ether.
- the combined filtrates are concentrated on a rotary evaporator and the residue is fractionally distilled under high vacuum. There are 10:51 g (77% d. Th.) Of the title compound as a colorless liquid (bp. 48-5O 0 C / 1.4 mbar).
- the diazonium salt is added in portions to a solution of 6.68 g of sodium iodide (44.56 mmol) in 170 ml of acetone (evolution of gas).
- the reaction mixture is stirred for 4 h at room temperature, then added to 300 ml of ice-water and extracted three times with dichloromethane.
- the combined organic phases are dried over sodium sulfate and concentrated on a rotary evaporator.
- the residue is purified by chromatography on silica gel (mobile phase: cyclohexane / ethyl acetate 20: 1). There are obtained 5.72 g (41% of theory) of the title compound.
- microsomes are prepared from rat livers.
- the rat livers are incubated in double volume homogenization buffer [100 mM Tris / HCl, 0.2 M sucrose, 30 mM nicotinamide, 14 mM sodium fluoride, 5 mM dithiothreitol, 5 mM MgCl 2 , protease inhibitor cocktail (Sigma, Taufkirchen), pH 7.5] and homogenized (Dounce Homogenizer).
- the supernatant of a 10,000 g centrifugation is then centrifuged at 100,500 g.
- Pelleted microsomes are included in homogenization buffer diluted to 10 mg / ml protein and stored at -80 0 C.
- the reaction of trans, trans- [l- 3 H] -farnesyl pyrophosphate to [ 3 H] -qualences by the microsomal squalene synthase takes place under the following reaction conditions: rat liver microsomes (protein content 65 ⁇ g / ml), 1 mM NADPH, 6mM glutathione, 10% PBS, 10mM sodium fluoride, 5mM MgCl 2 , pH 7.5.
- the particular compound to be tested is dissolved in DMSO and added to the assay in a defined concentration.
- the reaction is started by addition of farnesyl pyrophosphate (final concentration 5 ⁇ M) and 20 kBq / ml trans, trans [l- 3 H] -farnesyl pyrophosphate and incubated for 10 min. incubated at 37 ° C. Subsequently, 200 .mu.l of the reaction solution are mixed with 200 .mu.l of chloroform, 200 .mu.l of methanol and 60 .mu.l of 5N sodium hydroxide solution and adjusted to 2 mM squalene.
- the exemplary embodiments in this test show IC 50 values in the range from 50 nM to 20 ⁇ M.
- mice Male NMRI mice are maintained in metabolic cages on normal rodent diet (NAFAG 3883).
- the light / dark cycle is 12 hours, from 6 am to 6 pm and from 6 pm to 6 am
- the animals are weighing between 25 g and 40 g in groups of 8-10 Animals used in the experiments. Food and drinking water are available to the animals ad libitum.
- the substances are orally administered according to their solubility in aqueous Traganth suspension (0.5%) or in Solutol HS15 / saline solution (20:80) with the gavage in a volume of 10 ml / kg body weight or in Solutol HS 15 / saline Solution (20:80) or DMSO / saline solution (20:80) injected subcutaneously.
- the corresponding control groups receive only the corresponding formulation agent without active ingredient.
- the animals are injected intraperitoneally with radioactively labeled 14 C-mevalonolactone.
- the extracted lipid fraction is taken up in 1 ml of isopropanol, transferred to scintillation vials with 15 ml of Ultima Gold ® scintillation fluid (Packard) and filled in a liquid scintillation counter (Beckman Coulter LS 6500) counted.
- the rate of synthesis of the radiolabelled 14 C squalene and the 14 C successor metabolites of the active substance treated animals is compared with the rate of synthesis of radiolabelled 14 C squalene and the 14 C consecutive metabolites of control-agent-only treated animals.
- mice Male Wistar rats are maintained on normal rodent diet (NAFAG 3883) in Makrolon ® type III cages. The light / dark cycle is 12 hours, from 6 am to 6 pm and from 6 pm to 6 am. The animals are used with a body weight between 150 g and 200 g in groups of 6-8 animals in the experiments. The feed is withdrawn from the animals 18-22 hours before the start of the search. Drinking water is available ad libitum until the end of the experiment.
- the substances are prepared according to their solubility in aqueous Traganth suspension (0.5%) or in Solutol HS15 / saline solution (20:80) with the gavage in a volume of 10 ml / kg body weight orally or also injected subcutaneously in Solutol HS15 / saline solution (20:80) or DMSO / saline solution (20:80).
- the corresponding control groups receive only the corresponding formulation agent without active ingredient.
- the animals are injected intraperitoneally with radioactively labeled 14 C-mevalonolactone.
- the extracted lipid fraction is taken up in 1 ml of isopropanol, transferred to scintillation vials with 15 ml of Ultima Gold ® scintillation fluid (Packard) and filled in a liquid scintillation counter (Beckman Coulter LS 6500) counted.
- the rate of synthesis of radioactively labeled 14 C squalene and the 14 C sequestered metabolites of the drug-treated animals is compared with the rate of synthesis of radioactively labeled 14 C squalene and the 14 C follow-on metabolites of control-agent-only control animals.
- the compounds according to the invention can be converted into pharmaceutical preparations as follows:
- the mixture of compound of the invention, lactose and starch is granulated with a 5% solution (m / m) of the PVP in water.
- the granules are mixed after drying with the magnesium stearate for 5 minutes.
- This mixture is compressed with a conventional tablet press (for the tablet format see above).
- a pressing force of 15 kN is used as a guideline for the compression.
- a single dose of 100 mg of the compound of the invention corresponds to 10 ml of oral suspension.
- the rhodigel is suspended in ethanol, the compound according to the invention is added to the suspension. While stirring, the addition of water. Until the completion of the swelling of Rhodigels is stirred for about 6 h.
- a single dose of 100 mg of the compound according to the invention corresponds to 20 g of oral solution.
- the compound of the invention is suspended in the mixture of polyethylene glycol and polysorbate with stirring. The stirring is continued until complete dissolution of the compound according to the invention.
- the compound of the invention is dissolved in a concentration below saturation solubility in a physiologically acceptable solvent (e.g., isotonic saline, glucose solution 5% and / or PEG 400 solution 30%).
- a physiologically acceptable solvent e.g., isotonic saline, glucose solution 5% and / or PEG 400 solution 30%.
- the solution is sterile filtered and filled into sterile and pyrogen-free injection containers.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006031176A DE102006031176A1 (de) | 2006-07-06 | 2006-07-06 | Substituierte Benzoxepino-isoxazole und ihre Verwendung |
PCT/EP2007/005711 WO2008003424A1 (de) | 2006-07-06 | 2007-06-28 | Substituierte benzoxepino-isoxazole und ihre verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2041144A1 true EP2041144A1 (de) | 2009-04-01 |
Family
ID=38542010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07785863A Withdrawn EP2041144A1 (de) | 2006-07-06 | 2007-06-28 | Substituierte benzoxepino-isoxazole und ihre verwendung |
Country Status (6)
Country | Link |
---|---|
US (1) | US20100016299A1 (de) |
EP (1) | EP2041144A1 (de) |
JP (1) | JP2009542590A (de) |
CA (1) | CA2656633A1 (de) |
DE (1) | DE102006031176A1 (de) |
WO (1) | WO2008003424A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2010041726A1 (ja) * | 2008-10-10 | 2010-04-15 | 第一三共株式会社 | 置換三環性ヘテロアリール化合物 |
US8465939B2 (en) * | 2010-03-02 | 2013-06-18 | Nox Technologies, Inc. | Aging-related circulating particle-associated lipoprotein B oxidase (apoBNOX) and inhibitors thereof |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
EP2567959B1 (de) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2401697A (en) * | 1996-06-20 | 1998-01-07 | Pfizer Inc. | 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors |
DE102004001871A1 (de) * | 2004-01-14 | 2005-09-01 | Bayer Healthcare Ag | Tricyclische Benzazepin-Derivate und ihre Verwendung |
-
2006
- 2006-07-06 DE DE102006031176A patent/DE102006031176A1/de not_active Withdrawn
-
2007
- 2007-06-28 WO PCT/EP2007/005711 patent/WO2008003424A1/de active Application Filing
- 2007-06-28 US US12/307,540 patent/US20100016299A1/en not_active Abandoned
- 2007-06-28 JP JP2009516987A patent/JP2009542590A/ja active Pending
- 2007-06-28 EP EP07785863A patent/EP2041144A1/de not_active Withdrawn
- 2007-06-28 CA CA002656633A patent/CA2656633A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2008003424A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008003424A1 (de) | 2008-01-10 |
JP2009542590A (ja) | 2009-12-03 |
CA2656633A1 (en) | 2008-01-10 |
DE102006031176A1 (de) | 2008-01-10 |
US20100016299A1 (en) | 2010-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1716118B1 (de) | Tetrahydrobenzo (d) azepin-2-on derivate und ihre verwendung zur behandlung von kardiovaskulären krankheiten | |
DD237510A5 (de) | Verfahren zur herstellung von substituierten imidazo-(1,5-a)pyridin-derivaten | |
WO2006072362A1 (de) | (5s) - 3 - [(s)-fluor (4-trifluoromethylphenyl) methyl] -5,6,7,8-tetrahydrochinolin-5-ol derivative und ihre verwendung als cetp-inhibitoren | |
DE3434947A1 (de) | Isoxazolcarbonsaeure-derivate, ihre herstellung und verwendung | |
DE102006012548A1 (de) | Substituierte Chromanol-Derivate und ihre Verwendung | |
WO2008003424A1 (de) | Substituierte benzoxepino-isoxazole und ihre verwendung | |
EP1608659A1 (de) | Benzofuro-1,4-diazepin-2-on-derivate | |
EP1966217A1 (de) | Neue, acyclisch substituierte furopyrimidin-derivate und ihre verwendung zur behandlung von kardiovaskulären erkrankungen | |
EP0973744A1 (de) | 2-amino-substituierte pyridine verwendbar zur behandlung von arteriosklerose und hyperlipoproteinemie | |
DE102004001871A1 (de) | Tricyclische Benzazepin-Derivate und ihre Verwendung | |
DE3911064A1 (de) | Substituierte 1,8-naphthyridine | |
DE19801646A1 (de) | Substituierte alpha,beta-annellierte Butyrolactone | |
WO2008155017A1 (de) | Substituierte bicyclische heteroarylverbindungen zur behandlung kardiovaskulärer erkrankungen | |
DE4135473A1 (de) | Triazaspirodecanon-methylchromane | |
AT391316B (de) | Neue thienyloxy-alkylamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
WO1997035839A1 (de) | Neue borneole, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung | |
DE60212153T2 (de) | Tetrahydropyranderivate und ihre verwendung als therapeutika | |
CH630887A5 (de) | Verfahren zur herstellung von 2-hydroxy-4-(2-naphthyl)-butan- oder -but-3-en-derivaten. | |
HU182470B (en) | Process for preparing 6,7-benzomorphan derivatives | |
DE2308064A1 (de) | Benzotriazocine, ihre salze, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
EP0182271B1 (de) | Neue Nb-quartäre Dibromderivate von Ajmalin, Isoajmalin, Sandwicin und Isosandwicin sowie diese Derivate enthaltende pharmazeutische Zubereitungen und Zwischenprodukte und Verfahren zu ihrer Herstellung | |
WO2006040002A1 (de) | Neue oxadiazinon-derivate und ihre verwendung als ppar-alpha-modulatoren | |
DE2200496A1 (de) | Chinolinderivate | |
AT375079B (de) | Verfahren zur herstellung von neuen trans-2,3,4,4a ,5,9b-hexahydro-1h-pyrido(4,3-b)indolen und ihren pharmazeutisch annehmbaren salzen | |
EP2563762B1 (de) | Verfahren zur herstellung substituierter pyridin- 2 - one |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090206 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BISCHOFF, HILMAR Inventor name: KOLKHOF, PETER Inventor name: BUCHMUELLER, ANJA Inventor name: GRIEBENOW, NILS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER SCHERING PHARMA AG |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100119 |